<code id='A40FE0027A'></code><style id='A40FE0027A'></style>
    • <acronym id='A40FE0027A'></acronym>
      <center id='A40FE0027A'><center id='A40FE0027A'><tfoot id='A40FE0027A'></tfoot></center><abbr id='A40FE0027A'><dir id='A40FE0027A'><tfoot id='A40FE0027A'></tfoot><noframes id='A40FE0027A'>

    • <optgroup id='A40FE0027A'><strike id='A40FE0027A'><sup id='A40FE0027A'></sup></strike><code id='A40FE0027A'></code></optgroup>
        1. <b id='A40FE0027A'><label id='A40FE0027A'><select id='A40FE0027A'><dt id='A40FE0027A'><span id='A40FE0027A'></span></dt></select></label></b><u id='A40FE0027A'></u>
          <i id='A40FE0027A'><strike id='A40FE0027A'><tt id='A40FE0027A'><pre id='A40FE0027A'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:46785
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In